QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.
Hosted on MSN2mon
New Product Offerings Support QIAGEN's Shares Amid Currency WoesTo support internal growth, QIAGEN invests heavily in research and development (R&D) for the menu expansion of its key platforms. R&D expenditures represented 8.9% of third-quarter sales ...
Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results